vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• First study participant randomized in Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes with data expected in second half of 2026
• Cadisegliatin intellectual property portfolio expanded
• Leadership team strengthened
HIGH POINT, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent corporate developments.
"The randomization of the first participant in our CATT1 Phase 3 trial earlier this month reflects our continued momentum in advancing cadisegliatin," said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics. "Cadisegliatin is designed to selectively activate glucokinase in the liver, a differentiated approach that may improve glycemic control and reduce the risk of hypoglycemia when used alongside insulin. Hypoglycemic episodes remain frequent, life-disruptive, and sometimes life-threatening for people with type 1 diabetes. We believe cadisegliatin could play a meaningful role in addressing this large unmet medical need."
Recent Company Highlights
First Study Participant Randomized in Cadisegliatin Phase 3 Trial. In August 2025, vTv Therapeutics announced that the first study participant was randomized in the Company's CATT1 Phase 3 Trial evaluating cadisegliatin as an adjunctive therapy to insulin for the treatment of T1D. Topline data from the study is expected in the second half of 2026. (link to press release)
Patent Allowance for Crystalline Salt Form of Cadisegliatin. In August 2025, the United States Patent and Trademark Office allowed claims for a patent application directed to compositions of matter of crystalline forms of salts and co-crystals of cadisegliatin. The patent term runs through 2041. (link to press release)
Corporate Presentation at In June 2025, the Company participated in a virtual fireside chat as part of the H.C. Wainwright HCW@Home series. (link to webcast replay)
Appointment of Chief Financial Officer. In May 2025, vTv Therapeutics appointed Michael Tung, MD, MBA, as Chief Financial Officer. Dr. Tung brings over 20 years of financial management, investment experience, and strategic leadership across both private and public life sciences companies. (link to press release)
Second Quarter 2025 Financial Results
Cash Position: The Company's cash position as of June 30, 2025, was $25.9 million compared to $36.7 million as of December 31, 2024.
Research & Development (R&D) Expenses: R&D expenses were $4.1 million and $3.4 million in each of the three months ended June 30, 2025, and 2024, respectively. The increase reflects higher indirect costs primarily related to payroll expenses. This was partially offset by lower spending on cadisegliatin and other projects.
General & Administrative (G&A) Expenses: G&A expenses were $3.6 million and $3.7 million for each of the three months ended June 30, 2025, and 2024, respectively. The decrease was primarily due to decreases in other operating costs. This was partially offset by an increase in payroll related costs.
Other Income, Net: Other income for the three months ended June 30, 2025, was immaterial. Other income for the three months ended June 30, 2024, was $0.2 million and was driven by gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties.
Net Loss: Net loss attributable to vTv shareholders for the three months ended June 30, 2025, was $6.0 million or $0.92 per basic share. Net loss attributable to vTv shareholders for the comparable period a year ago was $5.2 million or $0.81 per basic share.
vTv Therapeutics Inc.Condensed Consolidated Balance Sheets(in thousands)
June 30,2025
December 31,2024
(Unaudited)
Assets
Current assets:
Cash and cash equivalents
$
25,922
$
36,746
Prepaid expenses
359
1,192
Other current assets
93
175
Total current assets
26,374
38,113
Property and equipment, net
16
28
Operating lease right-of-use assets
58
125
Total assets
$
26,448
$
38,266
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses
$
5,216
$
5,027
Current portion of operating lease liabilities
79
169
Total current liabilities
5,295
5,196
Contract liabilities, net of current portion
18,669
18,669
Warrant liability, related party
31
57
Warrant liability
48
43
Total liabilities
24,043
23,965
Commitments and contingencies
Stockholders' equity:
